Ocular Melanoma clinical trials at UCSF
1 research study open to eligible people
Ocular melanoma is a type of eye cancer. At UCSF, one trial examines the effects of combining Darovasertib with Crizotinib in advanced melanoma. Research is also being conducted to understand how genetic differences alter treatment effectiveness.
Showing trials for
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
open to eligible people ages 18 years and up
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
San Francisco, California and other locations
Last updated: